MTA acts at the intracellular level by inhibiting the MAT2A/PRMT5/RIOK1 axis, thereby weaponizing this pathway for PRMT5 vulnerability in cancer cells, and synergizing with pemetrexed (254–256). Here, PRMT5 is linked to cancer.